Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

ARVD (Arrythmogenic right ventricular cardiomyopathy) - updated task force criteria ppt


Published on

ARVD (Arrythmogenic right ventricular cardiomyopathy) - updated task force criteria ppt

  3. 3. ARVC - GENETICS “ARRYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY” • Genetic form of cardiomyopathy • Dominant mutations – - desmoplakin - cardiac ryanodine receptor - plakophilin 2 (PKP2) – younger age / malignant arrhythmias - transforming growth factor-β3 - desmoglein - 2 - desmocollin – 2 - TMEM43 (most recent – non desmosomal) • Recessive mutations – - junctional plakoglobin (JUP) – Naxos/Carvajal Syndrome • Familial occurrence of 30% to 50% • Genetic screening – - early detection of healthy carriers - prognostic role in patients
  4. 4. ARVC – Genetic mechanism “ARRYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY” • Mutations render desmosomes inappropriately sensitive to mechanical stresses, resulting in myocyte death • Signal transduction processes induced by mutant desmosome proteins can lead to reprogrammed myocyte cell biology so that these cells adopt a fibrofatty lineage
  5. 5. ARVC – Natural History “ARRYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY” • Typically present between the teenage years and the forties • Prevalence – 1:2000/1:5000 • Male : Female = 1:3 • Natural history characterized by four phases: - Concealed phase (asymptomatic, but at risk of SCD) - Overt clinical expression of an electrical system disturbance - Signs and symptoms of right ventricular failure - Frank biventricular congestive heart failure
  6. 6. ARVC – Clinical Presentation “ARRYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY” • Presenting symptoms varied - syncope - palpitations - sudden cardiac death - heart failure - occurs in a minority, but is the predominant mode of death in those protected from SCD by an ICD • ARVC accounts for 20% of cases of sudden cardiac death (among young athletes dying suddenly, the prevalence is higher)
  8. 8. The Need To Change The 1994 Criteria “ARRYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY” • 1994 criteria were highly specific, but lacked sensitivity for early and familial disease (clinical experience dominated by symptomatic index cases & SCD victims) • Additional ECG markers have been proposed in last 15 yrs • Genetic basis recognized - potential for mutation analysis • Experience in quantification of imaging criteria of ARVC ↑ • Newer imaging techniques – - contrast echo, 3D Echo - cardiovascular magnetic resonance with late enhancement - electroanatomic voltage mapping • Recognition that LV involvement may occur early
  9. 9. Framework of New Task Force Criteria “ARRYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY” The approach of classifying structural, histological, ECG, arrhythmic, and genetic features of the disease as major and minor criteria has been maintained • Global or regional dysfunction and structural alteration • Tissue characterization of walls • Repolarization abnormalities • Depolarization and conduction abnormalities • Arrhythmias • Family history Each category has major and minor criteria
  10. 10. Diagnostic Terminology for Revised Criteria “ARRYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY” • Definite diagnosis (from different categories): - 2 major or - 1 major and 2 minor criteria or - 4 minor • Borderline (from different categories): - 1 major and 1 minor or - 3 minor criteria • Possible (from different categories): - 1 major or - 2 minor criteria
  11. 11. CATEGORY I – “global or regional dysfunction and structural alteration” “ARRYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY” Major Criteria Minor Criteria Echo Regional RV akinesia, dyskinesia, or aneurysm : + 1 of the following - Regional RV akinesia /dyskinesia - + 1 of the following - PLAX RVOT ≥32 mm (≥19 mm/m2) PSAX RVOT ≥36 mm (≥21 mm/m2) Fractional area change ≤33% PLAX RVOT ≥29 to <32 mm (≥16 to <19 mm/m2) PSAX RVOT ≥32 to <36 mm (≥18 to <21 mm/m2) Fractional area change >33 to ≤40% MRI Regional RV akinesia, dyskinesia or dyssynchrony: + 1 of the following - RVEDV index: ≥110 mL/m2 (male) ≥100 mL/m2 (female) RV ejection fraction ≤ 40% RVEDVi : 100 - 110 mL/m2 (male) 90 - 100 mL/m2 (female) RV ejection fraction >40% to
  13. 13. Echocardiography in ARVC “ARRYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY” • Echo will remain the initial diagnostic approach of choice • Contrast echo - improved endocardial border delineation and enhanced RV opacification • The most conspicuous findings: - RV dilation - Enlargement of the RA - Isolated dilatation of the RVOT - Increased reflectivity of the moderator band - Localized aneurysms, decreased fractional area change, & akinesis/ dyskinesis of the inferior wall and the RV apex
  14. 14. PATIENT Mr X major/minor criteria? PLAX PSAX Echo Minor Criteria
  15. 15. Focal RV apical aneurysm –Echo Major Criteria
  16. 16. ECHO FEATURES OF ARVC Excessive trabeculations Hyperreactive moderator
  17. 17. Echocardiographic image with contrast of the RV of a 25 yr old man of a dilated RV clearly showing enhanced border delineation with a localized aneurysm (asterisk) of the RVOT.
  18. 18. Cardiac MR in ARVC “ARRYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY” • Midiri et al used five criteria for diagnosis of ARVC: (1) High signal intensity (substitution of myocardium by fat) (2) Ectasia of RVOT (3) Dyskinetic bulges (4) Right ventricular dilation (5) RA enlargement • Fibrosis is more specific than myocardial fat – detected by increased delayed enhancement in contrast CMR signal
  19. 19. End-diastolic and end-systolic frames of a short-axis cine magnetic resonance image showing an area of dyskinesia on free wall of a dilated RV, characterizing a focal ventricular aneurysm (arrows)
  20. 20. Axial T1-weighted black blood spin- echo cardiovascular MRI showing extensive transmural fatty replacement of the RV myocardium (arrow)
  21. 21. 30-80% of (advanced) cases have LV, as well as RV late GAD enhancement indicating focal fibrosis
  23. 23. CATEGORY II – “Tissue characterization of walls” “ARRYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY” Endomyocardial biopsy Major Criteria Minor Criteria NEW TFC Residual myocytes <60% by morphometric analysis (or <50% if estimated), with fibrous replacement of the RV free wall myocardium in ≥1 sample, with or without fatty replacement of tissue Residual myocytes 60%–75% by morphometric analysis (or 50%–65% if estimated), with fibrous replacement of the RV free wall myocardium in ≥1 sample, with or without fatty replacement of tissue OLD TFC Fibro-fatty replacement of myocardium
  24. 24. Figure 2. Endomyocardial biopsy findings in a proband affected by a diffuse form of ARVC/D. Marcus F I et al. Circulation 2010;121:1533-1541 Copyright © American Heart Association Endomyocardial biopsy findings in a proband affected by a diffuse form of ARVC/D. All 3 biopsy samples are from different regions of the RV free wall. There is extensive fibrofatty tissue replacement with myocardial atrophy, which is a major criterion (ie, residual myocytes <60% by morphometric analysis or <50% if estimated). Contributed by C. Basso, Padua, Italy.
  25. 25. Endomyocardial biopsy in ARVC “ARRYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY” • Definitive Dx - histologic demonstration of transmural fibrofatty replacement of RV myocardium at biopsy/surgery • In most patients, however, assessment of transmural myocardium is not possible • Dx based on RV endomyocardial biopsy specimens is limited because segmental nature of the disease causes false –ve • Use of electroanatomic voltage mapping to identify pathological areas for biopsy sampling may improve yield • RV free wall biopsy has a slight risk of perforation, but the more accessible IVS rarely exhibits histological changes
  26. 26. CATEGORY III – “Repolarization abnormalities” “ARRYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY” Electrocardiography Major Criteria Minor Criteria NEW TFC Inverted T waves in right precordial leads (V1, V2, and V3) or beyond in individuals >14 yrs of age (in the absence of complete RBBB QRS ≥120 ms) • Inverted T waves in leads V1 & V2 in individuals >14 yrs age (in the absence of complete RBBB) or in V4, V5, or V6 • Inverted T waves in leads V1, V2, V3, and V4 in individuals >14 years of age in the presence of complete RBBB OLD TFC Inverted T waves in right precordial leads (V2, and V3) in individuals >12yrs of age (in the absence of complete RBBB)
  27. 27. Major / Minor Criteria ? Major Criteria
  28. 28. Repolarization Abnormalities  Repolarization abnormalities are early and sensitive markers of disease expression in ARVC/D  T-wave inversion in V1, V2, and V3 and beyond in individuals >14 years of age who are otherwise healthy is observed in only 4% of healthy women and 1% of men. Therefore, it is reasonably specific in this population and considered a major diagnostic abnormality in ARVC/D Marcus FI. Prevalence of T-wave inversion beyond V1 in young normal individuals and usefulness for the diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Am J Cardiol. 2005; 95: 1070–1071.
  29. 29. CATEGORY IV – “Depolarization and Conduction Abnormalities” “ARRYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY” ECG Major Criteria Minor Criteria NEW TFC Epsilon wave in the right precordial leads (V1 to V3) • Late potentials by SAECG in ≥1 of 3 parameters (absence of a QRS ≥110 ms on standard ECG): - Filtered QRS duration ≥114 ms - Duration of terminal QRS <40 μV (low- amplitude signal duration) ≥38 ms - Root-mean-square voltage of terminal 40ms ≤20 μV • Terminal activation duration of QRS ≥55 ms from the nadir of the S to the end of QRS, incl. R´, in V1, V2, or V3, in the absence of complete RBBB OLD TFC Same Late potentials (SAECG)
  30. 30. Precordial leads of an ECG from a 44-year-old woman recorded during regular sinus rhythm, with an epsilon wave (arrow) in leads V1–V. The ECG shows a RBBB pattern. (Reproducible low-amplitude signals between end of QRS complex to onset of the T wave)
  31. 31. Figure 3. ECG from proband with T-wave inversion in V1 through V4 and prolongation of the terminal activation duration ≥55 ms measured from the nadir of the S wave to the end of the QRS complex in V1. Marcus F I et al. Circulation 2010;121:1533-1541 Copyright © American Heart Association
  32. 32. SAECG
  33. 33. CATEGORY V – “Arrhythmias” “ARRYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY” ECG/Holter/ Exercise Major Criteria Minor Criteria NEW TFC Nonsustained or sustained VT of left bundle branch morphology with superior axis (negative or indeterminate QRS in leads II, III, and aVF and positive in lead aVL) • Nonsustained or sustained VT of RV outflow configuration, left bundle branch block morphology with inferior axis (positive QRS in leads II, III, and aVF and negative in lead aVL) or of unknown axis • >500 VES per 24 h (Holter) OLD TFC • Left bundle-branch block-type ventricular tachycardia (sustained and nonsustained) • Frequent ventricular extrasystoles (>1000 per 24 hr)
  34. 34. AXIS? MAJOR/MINOR CRITERIA?? 12 lead ECG from a 25 y.o. man recorded during VT with a LBBB morphology and a slight-to-moderate right axis, typically originating from the RVOT. INFERIOR AXIS……MINOR CRITERIA
  36. 36. Exercise and ventricular arrhythmias • ARVD/C usually is characterized by the occurrence of symptomatic RV arrhythmias during exercise. • Fibrofat form arrhythmic substrate induced by adrenergic stimulation. • During exercise testing, 50% to 60% of patients with ARVD/C show ventricular arrhythmias: monomorphic LBBB pattern in 96% • The occurrence of arrhythmic cardiac arrest due to ARVD/C is significantly increased in athletes. Particularly in certain regions in Italy, ARVD/C has been shown to be the most frequent disease (22%) leading to exercise-induced cardiac death in athletes. • Diagnosis of ARVD/C is considered incompatible with competitive sports and/or moderate-to-high intensity level recreational activities.
  37. 37. CATEGORY VI – “Family history” “ARRYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY” Major Criteria Minor Criteria NEW TFC • ARVC confirmed in a first- degree relative who meets current task force criteria • ARVC confirmed pathologically at autopsy or surgery in a first-degree relative • Identification of a pathogenic mutation categorized as associated or probably associated with ARVC in the patient under evaluation • History of ARVC in a first- degree relative in whom it is not possible or practical to determine whether the family member meets current task force criteria • Premature sudden death (<35 years of age) due to suspected ARVC in a first- degree relative • ARVC confirmed pathologically or by current task force criteria in second- degree relative • Familial disease confirmed • Family history of premature sudden death (<35 years of age) due to suspected
  38. 38. Diagnosis of Familial ARVC “ARRYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY” In the context of proven ARVC/D in a first-degree relative, the diagnosis of familial ARVC/D is based on the documentation of one of the following in a family member: • T-wave inversion V1, V2, and V3 in individuals ≥ 14 years. • Late potentials by signal-averaged ECG (SAECG). • Ventricular tachycardia of LBBB morphology on ECG, Holter, or during exercise testing or >200 PVCs in 24 hours • Either mild global dilatation or reduction in RV ejection fraction with normal LV or mild segmental dilatation of the RV or regional RV hypokinesis.
  39. 39. MANAGEMENT “ARRYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY” There are five therapeutic options in patients with ARVD/C: • ICD therapy, • Antiarrhythmic agents, • Radiofrequency ablation, • HF treatment, and • Surgical treatment / cardiac transplantation
  40. 40. Recommendations for ICD in ARVC “ARRYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY” ACC/AHA 2006/2008 guidelines • Recommend ICD implantation for secondary prevention in all patients of ARVD/C with prior sustained VT or ventricular fibrillation • ICD implantation is reasonable for the prevention of SCD in patients with ARVD/C who have 1 or more risk factors for SCD
  41. 41. RISK STRATIFICATION & ICD USE “ARRYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY” ACC/AHA 2006/2008 guidelines Risk factors that have clinical utility in identifying patients with ARVD/C who are at risk for life-threatening ventricular arrhythmias include • Induction of VT during electrophysiological testing, • Detection of nonsustained VT on noninvasive monitoring, • Male gender, • Severe RV dilation, and extensive RV involvement • Young age at presentation (less than 5 years), • LV involvement, • Prior cardiac arrest, and unexplained syncope serve as markers of risk • Patients with genotypes of ARVD/C associated with a high risk for SCD should be considered for ICD therapy
  42. 42. Proposed recommendations for clinical management and prevention of sudden cardiac death in patients with ARVD Arrhythmogenic right ventricular dyplasia An article from the ESC Council for Cardiology Practice Fernández-Armenta J., Brugada J. Vol10 N°26 16 Apr 2012
  43. 43. Subgroups Risk markers Recommend - ations Follow-up ICD indication Definite ARVD High risk Aborted SCD Sustained VT Unexplained syncope Reduce physical exercise Avoid competitive sport β-blockers Annually : ECG, ECHO vs CMR Holter Exercise stress Recommended Definite ARVD Moderate risk Extensive disease (severe RV dysfunction, large LV involvement) Nonsustained VT SAME SAME Consider Definite ARVD Low risk Remaining patients with definite diagnosis of ARVD SAME SAME Not recommended
  44. 44. ROLE OF CATHETER ABLATION “ARRYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY” • Radiofrequency ablation has proven largely palliative due to patchy and progressive nature of the disease • RFA currently reserved for patients who experience frequent ventricular arrhythmias (and ICD shocks) despite optimal therapy with both ICDs and antiarrhythmic medication • Role of RFA may continue to increase in the future, as mapping techniques (CARTO) continue to evolve
  45. 45. Combined endocardial and epicardial substrate guided catheter ablation  Epicardial scar is wider than the endocardial scar in ARVD  Combined endocardial & epicardial substrate guided ablation resulted in a very good short- and mid-term success rate.  The high recurrence rate published in earlier series may be due to the conventional only- endocardial approach [Combined endocardial and epicardial catheter ablation in arvc. Brugada J.; Circulation: Arrhythmia and EP. 2012;5:111-121]
  46. 46. ARVC - CONCLUSIONS “ARRYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY” • SCD is the 3rd most common presenting symptom (behind syncope and palpitations) & the initial symptom in 23% cases • An increased awareness and prompt recognition of ARVC has considerable life-saving potential (ICD/transplant) • Revised TFC is more sensitive than the original TFC, and a quick diagnosis can be made with only history, ECG & Echo • Electrical/arrhythmic abnormalities precede morphological changes on echo/MRI: ECG has highest diag sensitivity -“this will have practical significance for the serial assessment of family members at risk of disease development”